Targeted therapy for stress urinary incontinence: a systematic review based on clinical trials

Pokrywczyńska, Marta; Adamowicz, Jan; Czapiewska, Monika; Balcerczyk, Daria; Jundziłł, Arkadiusz; Nowacki, Maciej; Petros, Peter

doi:10.1517/14712598.2016.1118459

Cited by 18 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several of the stem cell concepts have resulted in clinical trials, including ASCs, skeletal muscle cells, and myoblasts . While trials in humans are relatively novel, a recent systematic review of the literature identified 16 articles which met inclusion criteria which included 383 female patients . The mean cure and improvement rates in included patients over a 12‐month follow‐up were 37% and 33%, respectively.…”

Section: Stem Cell Technologiesmentioning

confidence: 99%

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence

Gomelsky

Athanasiou

Choo

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Urinary incontinence is a prevalent condition worldwide and causes a tremendous impact on a woman's quality of life. While conservative and non‐surgical therapies are options for treatment, surgery for stress urinary incontinence (SUI) is common. Options include colposuspension, slings (pubovaginal and midurethral), and periurethral bulking. While evidence supports each of these options in the treatment of SUI, each is associated with various rates of success and unique adverse event profiles. Urgency urinary incontinence (UUI) is initially treated with behavioral modification and pharmacologic means, with surgery reserved for those with refractory symptoms or significant complications from medication use. At present, intravesical onabotulinumtoxinA injections, percutaneous tibial nerve stimulation, and sacral neurostimulation are all viable options for refractory UUI/overactive bladder. As with surgical interventions for SUI, each of these is, likewise, associated with unique outcomes and adverse event profiles. Herein, we summarize the findings and conclusions from the 6th International Consultation on Incontinence (ICI) regarding surgical treatment of urinary incontinence in women.

show abstract

Section: Stem Cell Technologiesmentioning

confidence: 99%

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence

Gomelsky

Athanasiou

Choo

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…The objective cure and recurrence rates reported at 12 months follow up were 20–40% and 50–70%, respectively. No major adverse events occurred during the study timeframe …”

Section: Methodsmentioning

confidence: 99%

Applicability of regenerative medicine and tissue engineering for the treatment of stress urinary incontinence in female patients

Zambon

Williams

Bennington

et al. 2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

Stress urinary incontinence (SUI) is an age health‐related issue that generates interest due to its considerable public health burden and the controversies surrounding treatment. It is highly prevalent affecting 30–40% of all women during their lifetime. Midurethral slings are the standard of gold standard treatment for female patients with SUI. They have excellent short‐term cure rates; however, their efficacy tends to decrease over time and patients often report urinary incontinence recurrence. This paper addresses the applicability of regenerative medicine and tissue engineering for the treatment of SUI in female patients. Cell‐based treatment with periurethral injection of autologous adipose or muscle‐derived stem cells have been used for SUI; however, the cure rates and SUI recurrence at 1 year were 40% and 70%, respectively. Novel minimally invasive approaches, such as low‐intensity extracorporeal shock wave therapies have shown promising results in SUI animal models. In addition, local injection of growth factors, chemokines, and specific antibodies have shown histological evidence of neoangiogenesis, nerve, and sphincter regeneration in rodents and nonhuman primates with SUI. The use of bioactive factors and proteins secreted by cells, which is called secretomes, have been recognized as key regulators of various mechanisms, such as immunomodulation, angiogenesis, inflammation, apoptosis, and tissue repair. Emerging therapies aiming to replace or restore tissues and organ functionality may improve the long‐term efficacy and in the near future may represent the standard of care for the treatment of SUI.

show abstract

“…Clinical trials for restoring a damaged urethral sphincter have been carried out by cell transplantation of autologous myocytes, muscle‐derived stem cells and adipose tissue‐derived cells . However, after examining the results of these clinical trials, one review article concluded that cell‐based therapy, as practiced today, is “a safe but ineffective method” for stress urinary incontinence treatment . Such a negative conclusion was lead to in comparison with what standard therapy – an artificial urethral sphincter – can attain.…”

Section: Human Clinical Trialsmentioning

confidence: 99%

Regenerative medicine for urological tissues: Updated review 2018

Kanematsu

2018

Int J of Urology

View full text Add to dashboard Cite

The focus of the present review on regenerative medicine is limited; first, on a few human clinical trials carried out thus far in the urology field, and second, on more basic but important biological progress that regenerative medicine has brought us. Clinical trials for the bladder, urethra and urethral sphincter have been carried out thus far. Reconstruction with autologous cell-seeded biomaterial failed in patients in need of bladder augmentation. The strategy succeeded for urethral reconstruction in patients who might not have required this approach. Sphincter function improvement was attained by cell therapy, but did not equal the conventional standard therapy - the artificial sphincter. The radical progress in regenerative medicine is reported in more basic stem cell technology. The strategy to induce therapeutic cells from inducible pluripotent stem cells has shed novel light on developmental biology. In vitro creation of novel kidney tissue from inducible pluripotent stem cells has been attained. Other kinds of therapeutic cells could also be induced from the inducible pluripotent stem cells. Research should be encouraged to fill the gap between patient needs and what current regenerative medicine can attain.

show abstract

Targeted therapy for stress urinary incontinence: a systematic review based on clinical trials

Cited by 18 publications

References 39 publications

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence

Applicability of regenerative medicine and tissue engineering for the treatment of stress urinary incontinence in female patients

Regenerative medicine for urological tissues: Updated review 2018

Contact Info

Product

Resources

About